BNET Industries
Memory Pharmaceuticals Corp. (MEMY) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $11.5M
- Profit
- Dec 31 2007
- ($35.2M)
- Market Cap
- Sep 04 2008
- $25.5M
Latest News and Analysis
Memory Pharmaceutical Q4 2007 Earnings Call Transcript
Memory Pharmaceutical Q4 2007 Earnings Call Transcript
Additional Resources
Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
- Results in Proceeds of $2.0 Million - MONTVALE, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that it has secured $2.0 million through the sale of approximately 4.7 million shares of common stock at $0.42 per share under its June 2007 equity financing...
Memory Pharmaceuticals Presents Positive Preclinical Data for MEM 68626 at ICAD 2008
MONTVALE, N.J., July 30 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today presented preclinical data for MEM 68626, its lead 5-HT6 antagonist drug candidate, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease ICAD in Chicago. The results demonstrate that MEM 68626 is effective in models of cognition...
Memory Pharmaceuticals Closes Second Tranche of Equity Financing with The Stanley Medical Research Institute
- Results in Proceeds of $2 Million - MONTVALE, N.J., June 24 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that it has secured $2 million through the sale of approximately 4.7 million shares of common stock under its equity financing agreement with an...
Investigate Emerging Diagnostic Technologies for Use in Psychiatric Indications
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/fc91d1/emerging_diagnosti) has announced the addition of Decision Resources, Inc.'s new report "Emerging Diagnostic Technologies for Use in Psychiatric Indications" to their offering. Introduction The diagnosis of psychiatric diseases is an inexact science and a slow process for...
Now In Its Fourth Year, 'The CNS Market 2008 Report' Is an Expanded and Updated 400 Page Report of Brain and Nervous System Markets and Treatments
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/ab0827/the_cns_market_200) has announced the addition of the "The CNS Market 2008 Report" published by NeuroInsights to their offering. Drugs, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease...
Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
- Company to Request a Hearing - MONTVALE, N.J., June 9 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that on June 6, 2008 it received a letter from the NASDAQ Listing Qualifications Department notifying the Company that, because it has not regained compliance...
Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
MONTVALE, N.J., May 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans. ...
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
MONTVALE, N.J., May 14 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today reported its financial results for the first quarter ended March 31, 2008. "We had a productive start to 2008, reporting significant progress with our collaborations and refocusing our operations to advance four high-value programs," said Vaughn...
Memory Pharmaceuticals to Host R&D Day on May 16, 2008
MONTVALE, N.J., May 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. , today announced that it will host an R&D Day for the investment community on Friday, May 16, 2008 in New York City. Presentations will begin at 9:00 a.m. EDT and will focus on the Company's progress with its nicotinic...
Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
MONTVALE, N.J., May 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. announced today that it will report its first quarter 2008 financial results on Wednesday, May 14, 2008, before the U.S. financial markets open. Management will provide a Company update and discuss the first quarter results during a conference...
Memory Pharmaceuticals Corp. Changes and Reallocates Programs.
M2 PRESSWIRE-12 March 2008-NASDAQNEWS: Memory Pharmaceuticals Corp. Changes and Reallocates ProgramsC1994-2008 M2 COMMUNICATIONS LTD RDATE:13032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do you have...
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
-Expands PDE10 Collaboration with Amgen- -Company to Host Conference Call at 9:00 A.M. EDT- MONTVALE, N.J., March 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that it has realigned its operations, reallocated its resources and extended the preclinical research portion of its PDE10 collaboration...
Has added Memory Pharmaceuticals Corp. to their watch list.
M2 PRESSWIRE-12 March 2008-The Maybach Review: Has added Memory Pharmaceuticals Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:12032008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers,...
Memory Pharmaceuticals Corp. Reports the Fourth Quarter and Year end Results.
M2 PRESSWIRE-7 March 2008-NASDAQNEWS: Memory Pharmaceuticals Corp. Reports the Fourth Quarter and Year end ResultsC1994-2008 M2 COMMUNICATIONS LTD RDATE:07032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world...
Has added Memory Pharmaceuticals Corp. to their watch list.
M2 PRESSWIRE-7 March 2008-MG Strategies: Has added Memory Pharmaceuticals Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:07032008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers, researchers,...
Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
- Completes SAD Portion of the Phase 1 Program for R4996/MEM 63908 - MONTVALE, N.J., March 6 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. , a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system...
Global Market Review on Memory Pharmaceuticals Corp.
M2 PRESSWIRE-6 March 2008-Market Review: Global Market Review on Memory Pharmaceuticals Corp.C1994-2008 M2 COMMUNICATIONS LTD RDATE:06032008 Streetinvesting.com has now resumed our progressive review of Memory Pharmaceuticals Corp. (Nasdaq: MEMY) after it traded down 8% Thursday, late in the morning...
Has added Memory Pharmaceuticals Corp. to their watch list.
M2 PRESSWIRE-29 February 2008-NASDAQNEWS: Has added Memory Pharmaceuticals Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:29022008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate....
Progressive Review for Memory Pharmaceuticals Corp.
M2 PRESSWIRE-28 February 2008-Market Review: Progressive Review for Memory Pharmaceuticals Corp.C1994-2008 M2 COMMUNICATIONS LTD RDATE:28022008 Streetinvesting.com has now resumed our progressive review of Memory Pharmaceuticals Corp. (Nasdaq: MEMY) after it traded unchanged Thursday, early in the afternoon with below...
- Next »
- page 1 of 1
- « Previous
Sort byClose
- Incorporated: 1997
- CEO: Mr. Vaughn M. Kailian
Memory Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of a range of central nervous system (CNS) conditions. These conditions include neurological diseases associated with aging, such as Alzheimer's disease, and also include certain psychiatric disorders, such as schizophrenia, bipolar disorder and depression. As of Dec 31 2006, Co.'s drug development pipeline included four programs (an L-type calcium channel modulator, nicotinic alpha-7 agonists, PDE4 inhibitors and PDE10 inhibitors) with drug candidates in clinical and preclinical stages, as well as several other compounds with potential in the early-stage pipeline.
Key Competitors
Memory Pharmaceuticals Corp. Company Info
Board of Directors
Mr. Jonathan J. Fleming
Chairman
Mr. Michael E. Meyers
Mr. James R. Sulat
Dr. Paul Blake M.D.
Mr. Vaughn M. Kailian
Dr. Anthony B. Evnin Ph.D.
Dr. David A. Lowe Ph.D.
Mr. Peter F. Young
Dr. Walter Gilbert Ph.D.
Mr. Robert I. Kriebel
Contact Information
100 Philips Parkway
Montvale, NJ
201 802-7100
